The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants

Not Applicable

Completed

• Conditions: Indomethacin Therapy; Patent Ductus Arteriosus

• Registration Number: NCT00500305
• Lead Sponsor: University of Virginia

Brief Summary

A patent ductus arteriosus (PDA) is associated with increased morbidity in premature infants. Standard indomethacin treatment is associated with intestinal and renal morbidity. B-type natriuretic peptide is elevated in significant PDAs. This study will determine whether BNP guided therapy could reduce doses of indomethacin.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-04
• Study Completion: 2007-03
• Study First Submitted: 2007-07-10
• Study First Submitted QC: 2007-07-10
• Study First Posted: 2007-07-12
• Status Verified: 2018-05
• Last Update Submitted: 2018-05-01
• Last Update Posted: 2018-05-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Infants with echocardiographically confirmed PDA
• Infants determined by attending physician to require PDA closure

Exclusion Criteria

• infants with congenital hearts disease
• infants with creatinine value > 2.0

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Number of indomethacin doses given on study	2 days

Secondary Outcome Measures

Name	Time	Method
Rate of Chronic lung disease	36 weeks corrected gestational age
rate of PDA ligation	Discharge from NICU